| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 89.30▲ | 89.08▲ | 88.97▲ | 86.48▲ | 88.56▲ |
| MA10 | 89.30▲ | 88.81▲ | 88.23▲ | 87.79▲ | 88.68▲ |
| MA20 | 89.19▲ | 88.03▲ | 87.26▲ | 87.96▲ | 89.28▲ |
| MA50 | 88.88▲ | 86.68▲ | 86.86▲ | 88.04▲ | 95.43▼ |
| MA100 | 88.18▲ | 86.98▲ | 88.28▲ | 89.52▼ | 87.11▲ |
| MA200 | 87.27▲ | 88.42▲ | 87.59▲ | 92.80▼ | 71.93▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.016▼ | 0.087▲ | 0.301▲ | -0.092▼ | 0.389▲ |
| RSI | 62.302▲ | 77.916▲ | 76.681▲ | 54.110▲ | 48.692▼ |
| STOCH | 52.141 | 87.965▲ | 92.640▲ | 26.836 | 55.262 |
| WILL %R | -13.235▲ | -1.793▲ | -1.161▲ | -42.213 | -32.008 |
| CCI | 70.508 | 99.235 | 119.390▲ | 15.065 | 8.381 |
|
Friday, January 18, 2019 01:44 PM
A Phase 3 clinical trial, RESOLVE, evaluating AbbVie's (NYSE:ABBV) IMBRUVICA (ibrutinib) plus chemo in patients with metastatic pancreatic cancer failed to achieve the primary endpoint.
|
|
Friday, January 18, 2019 01:29 PM
NORTH CHICAGO, Ill., Jan. 18, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced an update on the Phase 3 RESOLVE trial (PCYC-1137 ...
|
|
Friday, January 18, 2019 09:48 AM
A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 18/01/19 | 87.895 | 89.43 | 86.92 | 89.385 | 5,278,107 |
| 17/01/19 | 85.54 | 87.685 | 85.42 | 87.20 | 6,438,679 |
| 16/01/19 | 85.66 | 86.39 | 85.45 | 85.55 | 4,926,980 |
| 15/01/19 | 84.93 | 85.68 | 84.45 | 85.50 | 7,295,930 |
| 14/01/19 | 86.97 | 86.97 | 84.49 | 84.76 | 6,368,939 |
| 11/01/19 | 87.54 | 88.31 | 87.54 | 88.31 | 5,318,114 |
| 10/01/19 | 87.88 | 88.88 | 87.12 | 88.20 | 6,527,679 |
| 09/01/19 | 90.88 | 91.39 | 87.46 | 87.81 | 9,971,898 |
| 08/01/19 | 91.20 | 92.30 | 90.40 | 90.79 | 7,478,264 |
| 07/01/19 | 90.07 | 90.757 | 89.20 | 90.37 | 7,281,459 |
|
|
||||
|
|
||||
|
|
||||
|
|